P-038 Phase I Trial of MCARH109, a First-in-Class G Protein Coupled Receptor Class C Group 5 Member D (Gprc5d)-Targeted CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma: Updated Analysis